Cargando…

In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study

Detalles Bibliográficos
Autores principales:	Minnema, Monique C., Jacobs, Joannes F. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663556/ https://www.ncbi.nlm.nih.gov/pubmed/36376268 http://dx.doi.org/10.1038/s41408-022-00751-0

Ejemplares similares

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
por: Long, Thorir Einarsson, et al.
Publicado: (2022)

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)
por: Rögnvaldsson, Sæmundur, et al.
Publicado: (2021)

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
por: Sigurbergsdóttir, Aðalbjörg Ýr, et al.
Publicado: (2023)

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
por: Rögnvaldsson, Sæmundur, et al.
Publicado: (2021)

Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
por: Rögnvaldsson, Sæmundur, et al.
Publicado: (2023)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

EBV-related lymphoma after long-term daratumumab treatment: a case report
por: Verpoorte-Botden, Ilse P. G., et al.
Publicado: (2020)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
por: Chen, Yunxin, et al.
Publicado: (2021)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

We need to stop looking for something that is not there….
por: Kendall, Marilyn, et al.
Publicado: (2014)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Reference intervals for steroid hormones in healthy 6- to 15-year-old girls based on liquid chromatography-tandem mass spectrometry in China
por: Wang, Jia-Li, et al.
Publicado: (2020)

Climate change and health—Stopping the merchants of doubt
por: Kentros, Peter A.
Publicado: (2020)

P894: INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY
por: Ros Levy, Marina, et al.
Publicado: (2023)

Recent advances in QM/MM free energy calculations using reference potentials()
por: Duarte, Fernanda, et al.
Publicado: (2015)

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
por: Palmason, Robert, et al.
Publicado: (2022)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Lessons learned from COVID-19 to stop future pandemics
por: Cueni, Thomas
Publicado: (2023)

Defining the Newborn Blood Spot Screening Reference Interval for TSH: Impact of Ethnicity
por: Peters, Catherine, et al.
Publicado: (2016)

Cavity-free plasmonic nanolasing enabled by dispersionless stopped light
por: Pickering, Tim, et al.
Publicado: (2014)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Painless Colonoscopy: A Pilot Study of a 5.9-mm Endoscope for Routine Colonoscopy
por: Yang, You-Lin, et al.
Publicado: (2018)

Light chain deposition disease with low glomerular proteinuria and multiple myeloma: If you search you find
por: Gobbi, Laura, et al.
Publicado: (2021)

Parameter estimation without confidence intervals?
por: Fukuhara, Toru, et al.
Publicado: (2016)

Parameter estimation without confidence intervals?
por: Bae, Jong-Myon
Publicado: (2016)

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals
por: Shapiro, Daniel D., et al.
Publicado: (2023)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Comments on article by Pullakhandam et al: Reference cut-offs to define low serum zinc concentrations in healthy 1-19 year old Indian children and adolescents
por: Brown, Kenneth H., et al.
Publicado: (2022)

Correspondence on article by Pullakhandam et al. Reference cut-offs to define low serum zinc concentrations in healthy 1–19-year-old Indian children and adolescents
por: McDonald, Christine M., et al.
Publicado: (2022)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Defining post-COVID condition
por: Villar, Juan Carlos, et al.
Publicado: (2022)

WALANT Protocol: Stop before you block
por: Zargaran, David, et al.
Publicado: (2021)

GMSB with Light Stops
por: Delgado, Antonio, et al.
Publicado: (2015)

Sneaky light stop
por: Eifert, Till, et al.
Publicado: (2014)

The light stop window
por: Delgado, Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f6dlhug9bcgkugojacjoqv5utt